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ABSTRACT  
We present a microfluidic system suitable for parallel label-free detection of several biomarkers utilizing a compact 
imaging measurement system. The microfluidic system contains a filter unit to separate the plasma from human blood 
and a functionalized, photonic crystal slab sensor chip. The nanostructure of the photonic crystal slab sensor chip is 
fabricated by nanoimprint lithography of a period grating surface into a photoresist and subsequent deposition of a TiO2 
layer. Photonic crystal slabs are slab waveguides supporting quasi-guided modes coupling to far-field radiation, which 
are sensitive to refractive index changes due to biomarker binding on the functionalized surface. In our imaging read-out 
system the resulting resonance shift of the quasi-guided mode in the transmission spectrum is converted into an intensity 
change detectable with a simple camera. By continuously taking photographs of the sensor surface local intensity 
changes are observed revealing the binding kinetics of the biomarker to its specific target. Data from two distinct 
measurement fields are used for evaluation. For testing the sensor chip, 1 µM biotin as well as 1 µM recombinant human 
CD40 ligand wereimmobilized in spotsvia amin coupling to the sensor surface. Each binding experiment was performed 
with 250 nM streptavidin and 90 nM CD40 ligand antibody dissolved in phosphate buffered saline. In the next test 
series, a functionalized sensor chip was bonded onto a 15 mm x 15 mm opening of the 75 mm x 25 mm x 2 mm 
microfluidic system. We demonstrate the functionality of the microfluidic system for filtering human blood such that 
only blood plasma was transported to the sensor chip. The results of first binding experiments in buffer with this test chip 
will be presented. 
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1. INTRODUCTION  
Microfluidic technology with an integrated biosensor is of high interest for the development of point-of-care 
applications. Such microfluidic systems have the ability to perform biochemical analyses using small reagent volumes 
and to be adapted to specific customer needs [1]. Especially for blood filtration the small reagent volume needed in 
microfluidic systems is beneficial compared to conventional diagnostic devices in centralized facilities [2]. To separate 
plasma from whole blood different concepts were introduced such as special filter materials [3], designed filtration 
channels [2, 4], or separation via a membrane [5]. Combining microfluidic concepts with a biosensor results in compact, 
decentralized, and fast operating devices [6, 9]. Biosensors typically consist of a selective biological recognition 
component (receptor) connected directly to a transducer [7]. The transducer transforms the binding kinetics into a 
detectable signal. Using photonic crystal slabs (PCS) as the transducer a label-free, compact, and cost-efficient system 
may be realized [8-10]. PCS are waveguides with a periodic nanostructure in a high refractive index material supporting 
quasi-guided modes. These modes can be excited in transmission as well as in reflection and are visible as guided-mode 
resonances (GMRs) in the optical spectrum. They have an evanescent fraction propagating above the PCS surface and 
are thus sensitive to mass changes at the surface. By functionalizing the surface with, e.g., antibodies or aptamers, 
protein binding kinetics results in a wavelength shift of the GMR caused by refractive index changes. This can be tracked 
in real time with an optical read-out system [9-11]. Previously, for other microfluidic devices optical read-out of the 
resonance spectral position was evaluated with a sensitive spectrometer [9]. With our imaging read-out system the 
resulting shift of resonances in the transmission spectrum is converted into an intensity change in the specific color 
channel of a simple CMOS camera aligned to the resonance wavelength [12]. Especially for point-of-care applications a 
test chip, which is able to detect multiple biomarkers in whole blood, combined with a compact and portable read-out 
system is of high interest. Here, we present an approach for a disposable test chip to serve all these properties (figure 1). 
In section 2 the fabrication of the nanostructured transducer surface and the procedure for specific bio-functionalization 
are described. In section 3 experimental results for imaging measurement of binding kinetics are presented. By 
continuously taking photographs of the PCS surface locally functionalized with the specific capture molecule local 
intensity changes are observed. Section 4 discusses the design of the microfluidic chip and the integration with the 
biosensor. The functionality of the microfluidic system for human blood filtration is demonstrated. Results of first 
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binding experiments with 500 nM biotinylated bovine serum albumin dissolved in phosphate buffered saline are 
presented. Conclusions are drawn in section 5. 
 
Figure 1: Schematic of microfluidic system for detection of multiple biomarkers with filter unit and bonded sensor chip. Label-free 
read-out is performed with a compact imaging system and a camera. 
2. BIOSENSOR FABRICATION 
Photonic crystal slabs are fabricated via ultra violet (UV) nanoimprint lithography. First, the nanostructure is transferred 
from a glass master into a stamp consisting of polydimethylsiloxane (PDMS). Sylgard 184 and curing agent (both from 
DOW Corning) were mixed in a ration of 8:1 for 15 minutes in a mixing tube (IKA). The glass master is placed within a 
teflon adapter und poured over with the PDMS. To remove all bubbles from the PDMS it is evacuated for another 15 
minutes inside a vacuum chamber. Afterwards, the PDMS is hardened in an oven at 130°C for 20 minutes. The hardened 
PDMS is cut out of the teflon adapter and pulled of the glass master.  
For sample fabrication 25 x 25 mm
2
 glass substrates with a thickness of 1 mm are cleaned with acetone and isopropanol 
for 15 minutes each in an ultrasonic bath and then are dehydrated on a hotplate at 160°C for 10 minutes. After the glass 
substrate is cooled down the glass surface is activated with oxygen plasma for 2 minutes (HF power: 200W) to enhance 
the adhesion of the adhesion promoter and finally of the photoresist. Next 150 μl adhesion promoter (Amoprime from 
AMO GmbH) are spin coated for 30 seconds at 3000 rpm onto the substrate. The substrates are baked on a hotplate for 2 
minutes at 115°C and cooled down for another 2 minutes. Now 150 μl of the photoresist Amonil (AMO GmbH) are spin 
coated with the same parameters as used before to generate a 200 nm thick layer. For transferring the nanostructure into 
the photoresist, the PDMS stamp is pressed carefully into the resist. The substrate including the stamp on top is exposed 
for 80 seconds with an UV halogen lamp to harden the resist. After the PDMS is removed from the resist, a 70 nm thick 
high-index layer of TiO2 is deposited by reactive sputtering (figure 2a). The glass master and thus the fabricated PCS 
have a period of Λ = 350 nm, a structure depth of t = 100 nm, a duty cycle of 40:60, and a size of 25 x 25 mm2For 
experiments with a fluid cell the PCS is used in this size, for experiments with the microfluidic chip the PCS has to be 
cut in 15 x 15 mm² pieces before functionalization. 
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Figure 2: (a) Schematic structure of fabricated photonic crystal slab. (b) Schematic of the resulting molecules for the successive  
functionalization steps. 
 
To transform the PCS into a biosensor we first activate the surface with oxygen plasma for 5 minutes (HF power: 50W). 
Afterwards the PCS is transferred into a nitrogen-filled glovebox. It is cleaned in dry ethyl alcohol and in dry methyl 
alcohol each for 5 minutes. Then the whole TiO2 surface is silanated with the molecule (3-aminopropyl)triethoxysilane 
(APTES) by incubating the sample for 1 hour in a solution of 1% APTES in 25 ml methyl alcohol at room temperature. 
Subsequently the substrate is washed with plenty methyl alcohol and baked for 20 minutes on a hotplate at 110°C. To 
couple the ligand covalently to the APTES molecule on the surface 0.1 g 1,4-phenylene diisothiocyanate (PDC) is 
dissolved in 0.5 ml pyridine and 4.5 ml N,N-dimethylformamide (DMF) and the substrate is soaked for 2 hours in this 
solution (all chemicals from Sigma Aldrich). PDC acts as a linker between the APTES and the ligand and is reactive with 
any amino group modified substance. Again the sample is washed with plenty methyl alcohol. For the chemical bonding 
of the ligand the sample is taken out of the nitrogen atmosphere and placed in a humidity chamber. Now 1 μM ligand – 
biotinylated bovine serum albumin (BSA-biotin) or recombinant human CD40 ligand (PeproTech GmbH) – dissolved in 
sodium acetate buffer (pH 5.5) is placed in 0.5 μl drops on the PCS surface and is incubated over night in the humidity 
chamber. The next day the non-bound molecules are washed away with Dulbecco´s phosphate buffered saline (pH 7.4) 
(DPBS) (Lifetechnologies GmbH). To passivate the remaining functional groups of the PDC first 1 M ethanolamine-HCl 
(BIO RAD) and then 1 mg/ml bovine serum albumin (Sigma Aldrich) dissolved in DPBS cover the PCS surface for 30 
minutes. After each passivation step the sample is washed with DPBS. In figure 2b schematics of the resulting molecules 
for each functionalization step are shown.  
3. PROTEIN DETECTION WITH FLUID CELL 
First, we investigated the functionality of our sensor using a fluid cell. An o-ring is squeezed between the 25 x 25 mm² 
large biosensor and a glass substrate. For the analyte exchange two butterfly cannulas are pierced through the o-ring and 
all is fixed with two screwed substrate holders. Figure 3a depicts a photograph of the employed measurement system 
[12]. The imaging read-out system has an overall size of 13 cm x 3.5 cm x 4.9 cm and the whole lens system, two 
crossed polarizing filters and a light emitting diode (LED) are placed inside the metallic torso. The fluid cell within the 
sensor is placed between a parallelizing lens for the LED side and a focusing lens for the camera side and between two 
linear polarizing filters. Because of this arrangement only light interacting with the quasi-guided modes is transmitted 
through the biosensor to the CMOS sensor of a simple camera. Via the USB interface the LED and the camera are 
controlled with a computer as well as real-time data processing can be realized for noise minimization during the protein 
detection. Aligning the guided-mode resonance of the PCS to the falling edge of a colored LED the resonance shift due 
to binding kinetics of the protein results in an intensity reduction in the transmitted light [13]. This intensity change can 
be recorded with the camera by continuously taking pictures of the sensor surface during the protein binding process. 
The applicated protein binds to its respective target molecule on the sensor surface and causes corresponding to the local 
functionalization a local intensity reduction, as is shown in figure 3b.  
a) b) 
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Figure 3: (a) Photograph of the read-out system with fluid cell. (b) Difference image obtained by subtracting the first recorded image 
from the last image during the protein binding. The white encircled areas ‘1’ and ‘2’ mark the local intensity reduction caused by 
CD40 ligand antibody association and ‘Reference’ the reference field. 
 
For figure 4a and b the mean values of the two measuring fields and one reference field are calculated for each taken 
photograph and the resulting intensity values are plotted against time for each protein detection. To generate a baseline 
the fluid cell was filled with pure phosphate buffered saline. After seven minutes the pure buffer was replaced by the 
protein-buffer-solution ((a) 90 nM CD40 ligand antibody and (b) 250 nM streptavidin). Washing again with pure buffer 
the non-bound protein was washed away and the intensity decreases no longer. For both protein detections the 
association to the target protein is clearly visible while the reference signal does not show unspecific binding events. But 
the amplitude measured during the same protein detection results in different intensity reductions. This is caused on the 
one hand by the low protein concentration (90 nM or 250 nM) compared to the ligand concentration (1 μM) 
functionalized on the PCS surface and on the other hand by the position of the measuring fields. The closer a measuring 
field is placed to the stream, which is caused by the analyte exchange, the higher is the signal amplitude. Furthermore, 
different signal amplitudes can be observed comparing the intensity reductions caused by the association of CD40 ligand 
antibody (reduction of 4%) and streptavidin (reduction of 1.5%). Although the streptavidin concentration is higher then 
the CD40 ligand antibody concentration, the intensity is decreased much less than one might have expected. We attribute 
this to the higher molecular weight of the antibody with 150 kDa (streptavidin: 60 kDa) and thus the higher refractive 
index change on the surface. In summary, for both proteins association kinetics are detectable clearly. 
 
Figure 4: Association of (a) 90 nM anti-CD40 ligand in buffer to a surface functionalized with CD40 ligand and (b) 250 nM 
streptavidin in buffer to a biotinylated surface causes reduction of intensity over time. 
4. PROTEIN DETECTION WITH MICROFLUIDIC TEST CHIP 
Next we developed a microfluidic test chip with the size of 75 mm x 25 mm x 2 mm in cooperation with the company 
Microfluidic ChipShop GmbH. As figure 5a shows, the chip consists of two parts. The main chip includes a filler neck 
for the application of whole blood, capillary channels for blood transport, and a cavity for the sensor. The cover plate 
includes a filter membrane for blood filtration and an adhesive foil for sensor bonding. After removing the protective foil 
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from the adhesive foil, the 15 x 15 mm² large sensor is pressed in the allocated space. The adhesive foil ensures on the 
one hand the connection between microfluidic chip and the sensor and on the other hand the imperviousness of the whole 
system. The blood is spiked with the anticoagulant heparin to inhibit immediately occurring coagulation inside the 
capillary channels because of surface enlargement. 200 μl blood is aspirated with a pipette and has to be pressed into the 
capillary channels and through the filter membrane with a pressure of approx. 50 mbar. The cellular remain in the 
membrane and only the clear blood plasma (approx. 70-100 μl) is transported to the sensor field (figure 5b).  
 
 
 
 
 
 
Figure 5: (a) Computer aided-design of microfluidic main chip including filler neck for whole blood, capillary channels and cavity for 
sensor (top) plus cover plate including blood filter membrane and adhesive foil for sensor bonding (bottom). (b) Layout of 
microfluidic test chip and human blood injection with pipette through filter. (c) Association of 500 nM BSA-biotin in buffer detected 
with test chip causes reduction of intensity over time. 
 
To evaluate the functionality of our test chip we performed first binding experiments by immobilizing initially 1 μM 
BSA-biotin and then 1 μM streptavidin on the sensor surface. To simulate measurement conditions as they would be 
existent for binding experiments with whole blood 500 nM BSA-biotin dissolved in phosphate buffered saline are filled 
into the test chip. Immediately the test chip is placed inside our read-out system and pictures are taken continuously 
during the protein binding process. Figure 5c demonstrates a clear association of BSA-biotin visible in the transmitted 
light while again the reference does not show any unspecific binding events.  
5. CONCLUSION 
We investigated the functionality of our biosensor and our imaging read-out system by successfully performing 
detections of 90 nM CD40 ligand antibody as well as of 250 nM streptavidin. The simultaneous tracking of measuring 
fields and non-functionalized background surface holds particular promise for continuous calibration. Furthermore, we 
developed and demonstrated a microfluidic chip for blood filtration. First binding experiments of 500 nM BSA-biotin 
were performed using the test chip with the biosensor and strikingly binding events are visible in the signal sequence. 
However, measurements with whole blood provided too much background noise so that binding kinetics of biotin could 
not be identified precisely in the actual setting. The high viscosity of the blood causes a continuous in-flow onto the 
sensor surface for several minutes. Hence, more optimization effort has to be spent on this point. Nevertheless, this 
approach is promising for a disposable test chip for multiple protein detection in human blood applicable for point-of-
care applications. 
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